Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer.

Autor:	Xia RJ; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China.; Department of Medicine, Northwest Minzu University, Lanzhou 730050, Gansu Province, China., Du XY; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China.; Department of Medicine, Northwest Minzu University, Lanzhou 730050, Gansu Province, China., Shen LW; Department of Medical Support Center, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China., Ma JG; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China., Xu SM; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China., Fan RF; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China., Qin JW; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China., Yan L; Department of General Surgery, The 940 Hospital of Joint Logistic Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China. lzzy940@163.com.
Jazyk:	angličtina
Zdroj:	World journal of gastrointestinal oncology [World J Gastrointest Oncol] 2024 Sep 15; Vol. 16 (9), pp. 3820-3831.
DOI:	10.4251/wjgo.v16.i9.3820
Abstrakt:	Despite the continuous developments and advancements in the treatment of gastric cancer (GC), which is one of the most prevalent types of cancer in China, the overall survival is still poor for most patients with advanced GC. In recent years, with the progress in tumor immunology research, attention has shifted toward immunotherapy as a therapeutic approach for GC. Programmed cell death protein 1 (PD-1) inhibitors, as novel immunosuppressive medications, have been widely utilized in the treatment of GC. However, many patients are still resistant to PD-1 inhibitors and experience recurrence in the advanced stages of PD-1 immunotherapy. To reduce the occurrence of drug resistance and recurrence in GC patients receiving PD-1 immunotherapy, to maximize the clinical activity of immunosuppressive drugs, and to elicit a lasting immune response, it is essential to research the tumor microenvironment mechanisms leading to PD-1 inhibitor resistance in GC patients. This article reviews the progress in studying the factors influencing the resistance to PD-1 inhibitors in the GC tumor microenvironment, aiming to provide insights and a basis for reducing resistance to PD-1 inhibitors for GC patients in the future. Competing Interests: Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article. (©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu